SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Steve Fancy who wrote (3551)1/7/1998 9:34:00 PM
From: Oliver & Co  Read Replies (1) of 6136
 
"Drop in HIV Level Parallels Reduction in Disease Progression
Risk"
Reuters Health Information Services (01/06/98)
ÿÿÿÿ To determine the value of using changes in both viral load
and CD4 cell counts to assess the prognosis of people with HIV, a
multicenter team from the University of Alabama in
Birmingham--led by Dr. Michael Saag--evaluated data for 1,330
HIV-positive people participating in seven antiretroviral therapy
trials. The researchers--who reported their findings in the
January issue of the Journal of Infectious Diseases--discovered
that the risk of clinical disease progression falls in proportion
to drops in HIV-1 RNA levels during the first six months of
treatment, but it rises with a lack of HIV RNA or CD4 response.
Based upon a comparison against subjects with a
non-syncytium-inducing phenotype, the researchers found that
patients with the syncytium-inducing phenotype had a 100 percent
higher risk of disease progression--a finding the researchers say
may suggest that viral phenotype is independent of patient
prognosis. The team concluded that both HIV-1 RNA and CD4
lymphocyte treatment responses and pretherapy levels should be
used to measure patient prognosis after the initiation of
antiretroviral therapy.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News